延迟实施长效抗逆转录病毒治疗对持续病毒血症HIV感染者的临床后果
该研究利用微模拟模型评估了在美国HIV持续病毒血症且依从性挑战的患者中延迟实施长效卡博特韦/利匹韦林(LA-CAB/RPV)的临床后果。模型假设队列33,600人,初始CD4计数150/µL,比较当前实践与立即/延迟完全实施及试验后实施等情景。结果显示立即完全实施可增加病毒抑制人年并减少死亡,而延迟实施则导致病毒抑制人年减少和死亡增加。
要点
- 每延迟一年完全实施,减少5,370病毒抑制人年并增加800例死亡。
- 在等待试验结果期间,应增加LA-CAB/RPV的实施并辅以强化支持服务。
核心结论
- 对于美国HIV持续病毒血症且间歇性参与照护的患者,使用LA-CAB/RPV可增加病毒抑制并降低死亡率。
- 在等待试验结果期间,应增加LA-CAB/RPV的实施并辅以强化支持服务。
研究设计与样本
- 使用微模拟模型,考虑两种方法:每日一线口服ART或LA-CAB/RPV,均辅以强化支持服务。
- 评估四种CAB/RPV实施情景:当前实践(1%使用CAB/RPV)、立即/延迟完全实施(0-4年后100%使用)、试验后实施(单臂试验后每年5% uptake;随机试验后每年15% uptake)和立即不完全实施(每年1%-20% uptake)。
- 队列规模33,600人,初始CD4计数150/µL,6个月病毒抑制率:口服ART 23%,LA-CAB/RPV 65%。
主要发现
- 单臂试验后实施比当前实践增加1,700病毒抑制人年并减少330例死亡;随机试验后实施增加1,280病毒抑制人年并减少270例死亡。
- 立即不完全实施每年3%和2% uptake分别与单臂试验后实施和随机试验后实施相似。
关键数值与推荐
- 延迟完全实施:每延迟一年减少病毒抑制人年5,370,增加死亡800例。
- 单臂试验后实施:增加病毒抑制人年1,700,减少死亡330例。
- 随机试验后实施:增加病毒抑制人年1,280,减少死亡270例。
临床怎么用
- 对于持续病毒血症且口服ART依从性挑战的HIV患者,应考虑使用LA-CAB/RPV。
- 实施LA-CAB/RPV时应辅以强化支持服务以最大化依从性。
- 在等待试验数据期间,不应延迟LA-CAB/RPV的实施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: People with HIV (PWH) with persistent viremia and adherence challenges to oral antiretroviral therapy (ART) can achieve viral suppression (VS) with long-acting cabotegravir/rilpivirine (LA-CAB/RPV). The US guidelines, however, recommend CAB/RPV only in limited situations. We projected the impact of delaying LA-CAB/RPV implementation while awaiting trial data. METHODS: Using a microsimulation model, we considered 2 approaches for PWH with persistent viremia and intermittent care engagement: daily first-line oral ART or LA-CAB/RPV, both with intensive-support-services (ISS) to maximize adherence. We evaluated 4 CAB/RPV implementation scenarios: (1) Current practice (1% on CAB/RPV); (2) hypothetical Immediate/Delayed complete implementation (100% CAB/RPV after 0-4 year); (3) 2 Post-trial implementation scenarios: Post-one-arm-trial implementation (1-year trial, 5% uptake/year thereafter), Post-randomized-trial implementation (3-year trial, 15% uptake/year thereafter; and (4) Immediate incomplete implementation (1%-20% uptake/year). Outcomes were virologically suppressed person-years (VSPY) and 5-yearmortality. Inputs included cohort size 33,600, initial CD4 count of 150/µL, 6-month-VS from observational data: 23% (oral ART), 65% (LA-CAB/RPV). RESULTS: Current practice projects 35 810 VSPY and 17 640 deaths at 5 years. Immediate complete implementation increases VSPY by 26 830 and averts 3980 deaths; Delayed complete implementation produces 5370 fewer VSPY and 800 more deaths/delayed year. Post-one-arm-trial implementation yields 1700 more VSPY and 330 fewer deaths than Current practice; Post-randomized-trial implementation yields 1280 more VSPY and 270 fewer deaths. Immediate incomplete implementation at 3% and 2% uptake/year is similar to Post-one-arm-trial implementation and Post-randomized-trial implementation. CONCLUSIONS: LA-CAB/RPV for US PWH with persistent viremia and intermittent care engagement would increase VS and decrease mortality. Increased LA-CAB/RPV implementation with ISS should be undertaken while awaiting trial results.
引用
- Pei PP, Jones M, Hu R, et al. Clinical Consequences of Delaying Implementation of Long-Acting Antiretroviral Therapy for People With HIV and Persistent Viremia in the United States. Clin Infect Dis. 2026. PMID: 40757869. doi:10.1093/cid/ciaf428
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。